Current role of selective internal radiation with yttrium-90 in liver tumors

http://www.futuremedicine.com/doi/abs/10.2217/fon-2016-0035

Posted online on March 23, 2016.
(doi:10.2217/fon-2016-0035)


Perspective
Current role of selective internal radiation with yttrium-90 in liver tumors
Wan Yee Lau*mce-anchor^,1mce-anchor, Yee Leong Teohmce-anchor²mce-anchor, Khin Maung Winmce-anchor³mce-anchor, Rheun-Chuan Leemce-anchor⁴mce-anchor, Vanessa H de Villamce-anchor⁵mce-anchor^,6mce-anchormce-anchor, Yun Hwan Joseph Kimmce-anchor⁷mce-anchor, Po-Chin Liangmce-anchor⁸mce-anchor, Ramon S Santos-Ocampomce-anchor⁹mce-anchor, Richard Hoau Gong Lomce-anchor¹⁰mce-anchor, Kieron Boon Leng Limmce-anchor¹¹mce-anchor, David Wai Meng Taimce-anchor¹²mce-anchor, David Chee Eng Ngmce-anchor¹³mce-anchor, Farah Gillan Iranimce-anchor¹⁰mce-anchor, Apoorva Gognamce-anchor¹⁰mce-anchor & Pierce Kah-Hoe Chow**mce-anchor^,14mce-anchor^,15mce-anchormce-anchor

*Author for correspondence: [email protected]
**Author for correspondence: [email protected]

An expert panel met to review the evidence for selective internal radiation therapy (SIRT) using yttrium-90 microspheres in hepatocellular carcinoma and metastases from colorectal cancer and neuroendocrine tumors. There is now convincing evidence for the safety and efficacy of SIRT in these situations albeit mostly from retrospective cohort studies. There are a number of ongoing prospective randomized controlled clinical trials investigating the role of SIRT in liver tumors; however, data from these trials are still several years away (although the SIRFLOX study has been recently published). In this evolving environment, published evidence and the authors’ experience were used to summarize the current and potential role of SIRT in the management of hepatocellular carcinoma of intermediate or advanced stage and in liver-dominant metastatic colorectal cancer and metastatic neuroendocrine tumors.

Anyone have access? Being HK & Singapore based may be some insights into Asian prevalent HCC.